Drug pricing will continue to be an important issue to federal and state regulators and legislators as health care partner Margaux Hall notes in a Law360 article.
Margaux explains that 2023 promises to be another eventful year for drug pricing with the Inflation Reduction Act implementation underway at the federal level, states government measures, and conflicts continuing between drug manufacturers, providers, payors and regulators regarding patient assistance programs, the scope of the Section 340B federal drug pricing program and other topics.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find our more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.